Z Z Z Z Zinc deficiency inc deficiency inc deficiency inc deficiency inc deficiency Zinc has a unique and extensive role in biological processes. Since the discovery of this element as an essential nutrient for living organisms (Raulin, 1869 , Maze, 1914 , Todd et al., 1934 , many diverse biochemical roles for it have been identified. These include roles in enzyme function (Vallee and Auld, 1990) , nucleic acid metabolism (Miller et al., 1967 , Brown et al., 1985 , cell signalling (McNulty and Taylor, 1999) and apoptosis (Zalewski et al., 1993) . Zinc is essential for physiological processes including growth and development (Prasad, 1985) , lipid metabolism (Cunnane, 1988) , brain and immune function (Prasad, 1985 , Endre et al., 1975 .
The importance of zinc for plant and animal metabolism has been recognised for many years. In 1969, zinc was shown to be essential for growth of Aspergillus niger, the common bread mould (Raulin, 1869) . Subsequently zinc was found to be essential for plants (Maze, 1914) and for normal growth of rats and mice (Todd et al., 1934) . It is only more recently that zinc deficiency in humans was identified. In the first reported study, published in 1961, symptoms of severe anemia, growth retardation, hypogonadism, skin abnormalities, geophagia and mental lethargy described in men from Iran, were attributed to nutritional zinc deficiency (Prasad et al., 1961) . Subsequently, there were many other reports (Prasad et al., 1963a , Prasad et al., 1963b and the recognition that nutritional zinc deficiency is a potentially widespread problem, not only in developing countries, but also in highly industrialised ones (Sandstead, 1991) .
While dietary factors that reduce the availability of zinc are the most common cause of zinc deficiency, inherited defects can also result in zinc deficiency. Both nutritional and inherited zinc deficiency produce similar symptoms. An outstanding feature of zinc deficiency is the broad range of pathologies produced. This is not surprising considering the number of physiological processes for which zinc is required and that over 300 mammalian enzymes are zinc-dependant (Vallee and Auld, 1990) . The initial effects of zinc deficiency include dermatitis, diarrhoea, alopecia and loss of appetite (Aggett, 1983 , Danks, 1990 . More prolonged deficiency results in growth impairment and neuropsychological changes such as emotional instability, irritability and depression (Halsted et al., 1972 , Prasad, 1991 , Vallee and Falchuk, 1993 . Immune deficiency syndromes have also been recorded, leading to increased susceptibility to infections and that may lead to the death of patients (Rodin and Goldman, 1969 , Julius et al., 1973 , Beach et al., 1980 . Data on the magnitude of zinc deficiency, whether nutritional or inherited, are difficult to obtain due to the lack of a simple and reliable method to determine body zinc status (Aggett, 1991; Hambidge, 2000; Ramakrishnan, 2002) . Plasma zinc concentrations are frequently used to estimate zinc status, however, this parameter may not be affected in mild zinc deficiency (Mack et al., 1989) and furthermore, plasma zinc levels are altered by infections or stress (King, 2000) . Even in severe zinc deficiency, plasma zinc concentrations can remain unchanged (Aggett and Comerford, 1995; Krebs and Hambidge, 2001 ).
Acrodermatitis enteropathica Acrodermatitis enteropathica Acrodermatitis enteropathica Acrodermatitis enteropathica Acrodermatitis enteropathica
Of the inherited forms of zinc deficiency, acrodermatitis enteropathica is the most commonly described condition. This rare, recessively inherited disorder was first reported by Wende in 1902 (Wende, 1902 ) but received its current name in 1942, when Danbold and Closs described it in more detail (Danbolt and Closs, 1942) . The symptoms of this condition included skin lesions, alopecia, diarrhoea, neuropsychological disturbances and reduce immune function and led to death of the patient in the absence of treatment (Aggett, 1983) . Acrodermatitis enteropathica was first identified as a zinc deficiency disease when it was discovered that the symptoms could be abolished by oral zinc supplementation (Moynahan, 1974) . Prior this finding, the antibiotic amphotericin B, which increases membrane permeability to divalent cations, was used effectively in the treatment of symptoms, presumably because the defective zinc transport system was bypassed (Aggett et al., 1981) . The defect in this disorder was shown to result in an impairment of zinc absorption in the gut, where patients with acrodermatitis enteropathica showed decreased intestinal absorption of 65 Zn (Weismann et al., 1979) and nett intestinal secretion of 65 Zn was reduced (Aggett et al., 1978) . Jejunal mucosal biopsies also showed reduced 65 Zn accumulation (Atherton et al., 1979) . Assays in cultured fibroblasts from patients with acrodermatitis enteropathica demonstrated a decreased rate of cellular zinc accumulation (Grider et al., 1998; Grider and Young, 1996) in some instances but not in others (Ackland et al., 1989) .
Histological studies on gut tissue from patients have shown that acrodermatitis enteropathica is associated with cellular abnormalities. Filamentous inclusion bodies in the cytoplasm (Mack et al., 1989; Bohane et al., 1977) and abnormal lysosomal inclusions (Jones et al., 1983) occur in the intestinal Paneth cells of patients. This pathology is considered to be a secondary effect of the disease because it disappears after zinc treatment. The inclusion bodies are not specific to acrodermatitis enteropathica, but are found in other diseases such as coeliac disease which may also be associated with zinc deficiency.
In acrodermatitis enteropathica the symptoms of zinc deficiency often first become manifest with the change from breast milk to cows milk (Neldner and Hambidge, 1975) , indicating the protective role of human milk, possibly due to the presence of low molecular binding agents, which increase zinc bioavailability (Arnaud and Favier, 1992) . Disturbances in lipid metabolism including reduced enteral absorption of unsaturated fatty acids also occur (Mack et al., 1989) . The plasma zinc levels in untreated patients with acrodermatitis enteropathica, are generally reduced (ranging from 0.33mmol/L to 8.1μmol/L) (Chandra, 1980; Ozkan et al., 1999; Anttila et al. 1984; Neldner and Hambidge, 1975; Weismann et al., 1983; Weismann et al., 1980; Aggett et al., 1981; Graves et al., 1980; Oleske et al., 1979; Walravens et al., 1978; Bohane et al., 1977; Kelly et al., 1976; Bronson et al., 1983) , although normal (11.5-22.5μmol/L) (Mack et al., 1989 , Chandra, 1980 and higher (23.2μg/g dry weight relative to normal 10.4-11.9μg/g dry weight) (Garretts and Molokhia, 1977) serum zinc levels have been reported. The variations in serum zinc in both nutritional and inherited forms of zinc deficiency suggest that serum zinc levels do not reflect overall body zinc status and that the symptoms of zinc deficiency may be due to a depletion of zinc from specific intracellular pools, for example membrane-bound zinc fractions (Jackson et al., 1984; Bettger and O'Dell, 1981) .
The gene responsible for acrodermatitis enteropathica was recently mapped to chromosome region 8q24.3 (Wang and Walsh, 2001) . Intensive search of this region identified a novel gene encoding a putative zinc-transporting molecule, ZIP4, which harboured a range of point mutations, splice-site modifications and deletions in patients with the disorder (Nakano et al., 2002; Wang et al., 2002; Kury et al., 2002) . The human ZIP4 gene shows high homology to other members of the ZIP (SLC39) family of metal uptake transporters. ZIP proteins have eight conserved transmembrane domains, often contain a histidinerich intracellular loop between transmembrane domains III and IV and are also rich in histidines at the extracellular amino terminus ( Fig.1) (Gaither and Eide, 2001) . The similarity of the ZIP4 protein with other members of the ZIP family is consistent with a proposed role for it in zinc transport into cells of the small intestine (Wang et al., 2002) . Further studies have demonstrated that expression of hZIP4 gene was restricted to small intestine, stomach, colon and kidney (Wang et al., 2002) . The mouse homologue of human ZIP4 protein was localised to apical surface of mature enterocytes, consistent with its function in uptake of dietary zinc in small intestine (Wang et al., 2002; Dufner-Beattie et al., 2003a) . Human cells over-expressing mZIP4 gene showed increased accumulation of 65 Zn which was concentrationdependant and saturable, indicating a carrier-mediated uptake process (Dufner-Beattie et al., 2003b) . Dietary zinc deficiency resulted in up-regulation of ZIP4 mRNA and protein in mouse small intestine and conversely, zinc supplementation produced the opposite effect (Dufner-Beattie et al., 2003a , Liuzzi et al., 2004 . In vitro studies on cells over-expressing mouse or human ZIP4 gene and also in vivo studies on mouse (Dufner-Beattie et al., 2003b) have shown that ZIP4 undergoes posttranscriptional regulation in response to zinc levels. In conditions of zinc deficiency, ZIP4 protein was concentrated on the plasma membrane of the cells whereas in zinc-replete cells ZIP4 was endocytosed and was mainly found in intracellular compartments. In addition to the gross mutations of the ZIP4 gene detected in acrodermatitis enteropathica such as frame-shifts, premature termination of protein and large deletions, some single amino acid missense mutations were identified mainly within conserved transmembrane domains. The effect of six such mutations on zinc transport was investigated by Wang et al. . Cultured cells containing these mutations showed a decrease in 65 Zn uptake. CHO cells stably expressing these different mutations showed variations in the amount of N-glycosylation of the ZIP4 protein. In addition, the ZIP4 protein was mislocalised and detected in the nuclear envelope and endoplasmic reticulum, in contrast to the plasma membrane where it was located in cells transfected with the wild-type allele. The mislocalisation of ZIP4 was attributed to misfolding of the protein, thus preventing its proper glycolysation and localisation. Two other mutants showed increased accumulation of ZIP4 at the plasma membrane relative to the control and a failure to response to changing zinc concentrations, suggesting a defect in a zinc sensing mechanism which controls mZIP4 trafficking .
Despite an intensive search, no modifications in coding, intronic or promoting sequence of ZIP4 gene could be found in some patients affected by acrodermatitis enteropathica (Kury et al., 2003) . This indicates a possible presence of yet unidentified regulatory region of ZIP4 gene, harbouring mutations in these individuals. Alternatively, another zinc transporter may be affected in some cases of acrodermatitis enteropathica (Kury et al., 2003) .
The lethal milk mouse The lethal milk mouse The lethal milk mouse The lethal milk mouse The lethal milk mouse Lethal milk is an inherited disorder of zinc deficiency occurring in mice. New born mice suckling dams with the "lethal milk" (lm) mutation develop zinc deficiency and die within a week. The lm mutation is an inherited disorder of zinc metabolism in mice which has provided an opportunity to investigate a specific lesion in zinc metabolism. Lethal milk is a recessive phenotype in mice caused by a mutation on chromosome 2 (Green, 1973) . The most prominent defect is found in the lactating dams. When suckled to a homozygous mutant dam, both normal (+/+) and lm /lm pups develop symptoms characteristic of nutritional zinc deficiency. This leads to death of the pups before weaning (Piletz and Ganschow, 1978) . Mutant pups survive if fostered to a normal dam. They also survive if zinc supplementation is given either to the pups (Piletz and Ganschow, 1978) or to the mothers (Erway and Grider, 1984) . This suggested a defect in the production of lm /lm milk, which causes a reduction in the amount or the availability of zinc to the pups.
In the lethal milk mouse, a defect in the secretion of zinc from the mammary gland was demonstrated where the zinc concentration in the milk was reduced by 34% relative to the normal (Piletz and Ganschow, 1978 , Ackland and Mercer, 1992 , Lee et al., 1992 . Zinc supplementation of pups or fostering them on normal dams reduced their mortality (Ackland and Mercer, 1992) . A nonsense mutation at arginine codon 297 in the ZnT4 zinc efflux transporter, resulting in premature protein termination, was reported to be responsible for this disorder (Huang and Gitschier, 1997) . ZnT4 belongs to ZnT (SLC30) family of metal transporters, which have 6 conserved transmembrane domains and histidine-rich zinc binding region between transmembrane domains IV and V (Fig.2) . These findings, together with the capacity of ZnT4 to confer zinc resistance when expressed in zinc-sensitive Δzrc1 yeast strain (Huang and Gitschier, 1997) and its ability to bind zinc (Murgia et al., 1999) , suggested that mouse ZnT4 plays a role in the transport of zinc from the breast into milk.
The zinc deficiency in the mutant milk is the most obvious feature of the lm/lm mutation, but it is not the only abnormality seen in these animals. In early adult life they are phenotypically normal, having survived the neonatal period by being fostered to a normal dam. However, in late adult life, mutant animals usually Zinc deficiency in premature breast fed infants Zinc deficiency in premature breast fed infants Zinc deficiency in premature breast fed infants Zinc deficiency in premature breast fed infants Zinc deficiency in premature breast fed infants An inherited form of zinc deficiency similar to that of the lethal milk mouse is found in humans. The disorder manifests itself in premature breast fed infants, who demonstrate symptoms characteristic to nutritional zinc deficiency including dermatitis, diarrhoea, alopecia, loss of appetite, impaired immune function and neuropsychiatric changes (Aggett et al., 1980 , Prasad, 1985 . This condition has been reported in pre-term babies (27 to 33 weeks gestation) (Aggett et al., 1980; Zimmerman et al., 1982; Weymouth et al., 1982; Connors et al., 1983; Parker et al., 1982; Heinen et al., 1995) and less commonly in term babies (Stevens and Lubitz, 1998; Khoshoo et al., 1992; Bye et al., 1985; Glover and Atherton, 1988) .
This zinc deficiency disorder found in premature babies is a consequence of reduced levels of zinc in the maternal milk (Sharma et al., 1988) . Analysis of maternal milk indicated zinc levels were less than 40% that of normal milk at matched weeks of lactation (Weymouth et al., 1982 , Zimmerman et al., 1982 . Maternal zinc deficiency was not responsible for the low zinc levels in the milk (Weymouth et al., 1982 , Zimmerman et al., 1982 . Pedigree analysis has indicated that the condition, which predisposes mothers to produce zinc-deficient breast milk, is inherited.
Oral zinc supplementation induced a remission of zinc deficiency in these babies. Maternal zinc supplementation, in most cases, did not increase zinc levels in milk (Weymouth et al., 1982 , Zimmerman et al., 1982 , Parker et al., 1982 , Connors et al., 1983 or maternal plasma zinc levels (Weymouth et al., 1982; Parker et al., 1982; Dorea, 2000) . Prematurity does not account for the zinc deficiency, despite the higher requirements of preterm babies for zinc due to rapid growth, however prematurity may lead to a predisposition to zinc deficiency. Premature babies are in negative zinc balance at birth because of the lower than in develop less dramatic symptoms of zinc deficiency (Erway and Grider, 1984) .
term babies capacity for gut absorption, however they regain positive zinc balance in few week after birth when fed on normal breast milk (Dauncey et al., 1977; Vileisis et al., 1981; Widdowson et al., 1974) . On zinc deficient milk, on other hand, their body zinc levels remain low (Aggett et al., 1980 , Zimmerman et al., 1982 , Weymouth et al., 1982 , Connors et al., 1983 , Parker et al., 1982 , Heinen et al., 1995 .
The aetiology of the zinc deficiency of neonates fed on breast milk is distinct from acrodermatitis enteropathica, in several ways. While zinc deficiency in the breast fed babies is caused by the low levels of zinc in the maternal milk, in acrodermatitis enteropathica the maternal milk is protective and the symptoms of zinc deficiency develop after weaning (Aggett, 1983) . No impairment in zinc uptake in the gut has been found in the breast fed zinc deficient babies (Aggett et al., 1980) . This is in contrast to acrodermatitis enteropathica, where mucosal zinc uptake in the small intestine of patients was lower than normal (Atherton et al., 1979) .
The clinical picture of the zinc deficiency found in premature babies is similar to that seen in the "lethal milk" mouse, previously described. The murine disorder is associated with a mutation in the ZnT4 gene, a member of the SLC30 family. The possibility that a defect in maternal hZnt4 was responsible for the production of zinc deficient milk in the mothers of the pre-term babies has been investigated. Sequence analysis of the reading frames of hZnT4 cDNA from lymphoblasts, fibroblasts and mouthwash buccal cells showed no differences between control individuals and mothers of the infants with zinc deficiency. Furthermore, no differences between hZnT4 mRNA levels in affected mothers and controls were found (Michalczyk et al., 2003) . Protein levels of hZnT4 in extracts of lymphoblasts, fibroblasts and buccal cells and the intracellular localisation of hZnT4 protein was similar in lymphoblast, fibroblast and buccal cells from mothers of the infants with zinc deficiency compared to controls. Interestingly, in all 3 cell types, the hZnT4 protein did not co-localise with intracellular pools of zinc detected with Zinquin, which may be in the vesicular secretory pathway. This suggests that the hZnT4 transporter may not be pumping zinc into zinc-containing vesicles that are destined for secretion (Michalczyk et al., 2003) . These results indicate that the 'lethal milk' mouse is unlikely to be the corresponding model for the human mammary zinc secretion disorder.
There are some differences between the mouse and human disorders, which support the conclusion that the human and murine disorders are different. In old age, the mouse shows symptoms of zinc deficiency (Piletz and Ganschow, 1978) , while zinc deficiency in women with defective zinc mammary secretion has not been reported. Maternal zinc supplementation in the "lethal milk" mouse is effective in alleviating pup zinc deficiency (Piletz and Ganschow, 1978) but maternal zinc supplementation in humans does not increase milk zinc levels (Weymouth et al., 1982 , Zimmerman et al., 1982 , Parker et al., 1982 , Connors et al., 1983 . Finally, utricular otoconia are absent in the "lethal milk" mouse (Erway and Grider, 1984) but abnormalities in balance, which might be a consequence of defective utricular otoconia have not been reported in humans.
Previous studies on the 'lethal milk' mouse (Ackland and Mercer, 1992) provide evidence for alternative zinc transporters apart from ZnT4. The milk produced by the 'lethal milk' mouse has a approximately one third reduction in zinc concentrations relative to the control, thus the rest gets through presumably by other transporters. Zinc in milk is bound to a number of different components including casein 14%, albumin 28%, low-molecularweight ligands 29% and fat 29% (Lonnerdal et al., 1982) . It is possible that different zinc transporters are involved in incorporation zinc into different types of vesicles, which deliver zinc into various milk components.
Several other members of the SLC30 have been screened to test the hypothesis that one or more of them may be responsible for impaired zinc secretion into the breast milk. Significantly reduced levels of hZnT5 and hZnT6 mRNA were detected in fibroblasts and lymphoblasts from two patients in comparison to corresponding controls (Michalczyk unpublished data) . These findings suggest that defects in hZnT5 and/or possibly hZnT6 may underlie the disorder of reduced zinc secretion into the milk.
In conclusion, the genetic basis of two inherited disorders of zinc deficiency, acrodermatitis enteropathica and the lethal milk mouse, is known. In another disorder of zinc deficiency found in humans and which results in the production of zinc-deficient milk, no mutations have been detected. As there are no definitive tests for zinc deficiency, it is considered that other zinc disorders may go undiagnosed. It is therefore likely that defects in other genes, in addition to ZnT4 and ZIP4, may contribute to the aetiology of zinc deficiency.
